Metastasectomy Improves Survival in Patients with Metastatic Urothelial Carcinoma
| Autor: | Yuta Takezawa, Aerken Maolake, Yusuke Shimura, Atsushi Mizokami, Takahiro Nohara, Kouji Izumi, Kazuyoshi Shigehara, Yoshifumi Kadono, Ariunbold Natsagdorj, Hiroaki Iwamoto |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Metastatic Urothelial Carcinoma Metastasis 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Progression-free survival Survival rate Aged Aged 80 and over Cisplatin business.industry Standard treatment Metastasectomy General Medicine Middle Aged medicine.disease Primary tumor Survival Rate Urinary Bladder Neoplasms 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology business medicine.drug |
| Zdroj: | Anticancer Research. 36:5557-5562 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.11140 |
| Popis: | Metastatic urothelial carcinoma is one of the most fatal urological malignancies. Cisplatin-based systemic chemotherapy is the standard treatment for metastatic urothelial carcinoma, and there is little evidence to support metastasectomy. The aims of the study were to evaluate the efficacy of metastasectomy and to investigate the prognoses of the patients. The study included 436 patients with urothelial carcinoma who were treated at our hospital. Of these, we included and retrospectively analyzed 29 patients who received curative treatment for the primary tumor and had been treated for metastases. Seven of these patients underwent metastasectomy. In a multivariate analysis, a serum C-reactive protein level before treatment for metastasis of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|